Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Rodgers

Showing results (261-270 of 356) with videos related to

Pageof 36
Sort By:
BMC Public Health|November 17, 2018
Cardiovascular disease risk and comparison of different strategies for blood pressure management in rural IndiaDevarsetty Praveen, David Peiris, Stephen MacMahon, et al.
Kidney International Reports|February 12, 2024
The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice DatasetMin Jun, James Wick, Brendon L Neuen, et al.
Hypertension (Dallas, Tex. : 1979)|December 21, 2018
Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes MellitusToshiaki Ohkuma, Min Jun, Anthony Rodgers, et al.
Lancet (London, England)|November 13, 2015
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysisXinfang Xie, Emily Atkins, Jicheng Lv, et al.
The Lancet. HIV|November 20, 2019
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trialJean-Michel Molina, Kathleen Squires, Paul E Sax, et al.
Journal of Hypertension|February 8, 2017
Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: an analysis of the PROGRESS and ADVANCE trialsEmily R Atkins, Yoichiro Hirakawa, Abdul Salam, et al.
BMJ (Clinical Research Ed.)|May 29, 2014
Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary careVanessa Selak, C Raina Elley, Chris Bullen, et al.
Lancet (London, England)|March 18, 2015
Worldwide access to treatment for end-stage kidney disease: a systematic reviewThaminda Liyanage, Toshiharu Ninomiya, Vivekanand Jha, et al.
Hypertension (Dallas, Tex. : 1979)|September 4, 2024
Use and Cost Patterns of Antihypertensive Medications in the United States From 1996 to 2021Joshua A Jacobs, Anthony Rodgers, Brandon K Bellows, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 20, 2019
Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance MutationsAlexander Wong, Deborah Goldstein, Josep Mallolas, et al.
Pageof 36

Showing results (261-270 of 356) with videos related to

Sort By:
Pageof 36
BMC Public Health|November 17, 2018
Cardiovascular disease risk and comparison of different strategies for blood pressure management in rural IndiaDevarsetty Praveen, David Peiris, Stephen MacMahon, et al.
Kidney International Reports|February 12, 2024
The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice DatasetMin Jun, James Wick, Brendon L Neuen, et al.
Hypertension (Dallas, Tex. : 1979)|December 21, 2018
Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes MellitusToshiaki Ohkuma, Min Jun, Anthony Rodgers, et al.
Lancet (London, England)|November 13, 2015
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysisXinfang Xie, Emily Atkins, Jicheng Lv, et al.
The Lancet. HIV|November 20, 2019
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trialJean-Michel Molina, Kathleen Squires, Paul E Sax, et al.
Journal of Hypertension|February 8, 2017
Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: an analysis of the PROGRESS and ADVANCE trialsEmily R Atkins, Yoichiro Hirakawa, Abdul Salam, et al.
BMJ (Clinical Research Ed.)|May 29, 2014
Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary careVanessa Selak, C Raina Elley, Chris Bullen, et al.
Lancet (London, England)|March 18, 2015
Worldwide access to treatment for end-stage kidney disease: a systematic reviewThaminda Liyanage, Toshiharu Ninomiya, Vivekanand Jha, et al.
Hypertension (Dallas, Tex. : 1979)|September 4, 2024
Use and Cost Patterns of Antihypertensive Medications in the United States From 1996 to 2021Joshua A Jacobs, Anthony Rodgers, Brandon K Bellows, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 20, 2019
Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance MutationsAlexander Wong, Deborah Goldstein, Josep Mallolas, et al.
Pageof 36